Abstract 168 Table 1
Endpoints AL/TTR Amyloid+HKTx (n=4) HKTx Control (n=26) Log-Rank P-Value
4 Year Survival 100.0% 80.8% 0.345
4 Year Freedom from CAV 75.0% 92.3% 0.265
4-Freedom from NF-MACE 100.0% 96.2% 0.695
4-Freedom from Any-Treated Rejection 100.0% 88.5% 0.476
4 Year Freedom from Acute Cellular Rejection 100.0% 96.2% 0.683
4 Year Freedom from Antibody-Mediated Rejection 100.0% 92.3% 0.568